Church & Dwight (CHD) Q3 2025 earnings review
Volume Rebounds to Drive Strong Beat; Full-Year Outlook Raised
Church & Dwight reported a significant rebound in Q3, with organic sales growing 3.4%, well ahead of expectations. The growth was entirely driven by a robust 4.0% increase in volume, signaling strong consumer demand and market share gains for its portfolio of brands. This performance, led by key franchises like THERABREATH and HERO, marks a sharp reversal from the weakness seen in the first half of the year. The newly acquired TOUCHLAND brand is also exceeding initial expectations. Consequently, management raised its full-year guidance for sales, gross margin, EPS, and cash from operations. The primary headwind remains the underperforming vitamin business, which is currently undergoing a strategic review.
🐂 Bull Case
The 4.0% volume growth demonstrates healthy underlying consumer demand and successful market share capture, a stark contrast to the volume declines seen earlier in the year.
Management raised its outlook across key metrics including sales, EPS, and cash flow, signaling confidence in sustained momentum for the remainder of the year.
High-growth brands like THERABREATH (+17% consumption) and HERO (+5.2% consumption) continue to vastly outperform their categories, with long growth runways due to low household penetration.
🐻 Bear Case
Organic growth was hampered by a -0.6% impact from price/mix, and -1.4% in the core Domestic segment, suggesting promotional pressures or a consumer shift to lower-priced value packs.
The vitamin business remains a significant headwind, offsetting growth in other areas and creating uncertainty pending the conclusion of its strategic review by year-end.
The Q4 organic growth outlook of 1.5% implies a significant deceleration from Q3's strong performance, attributed to a tough comparison from a prior year port strike and ongoing vitamin weakness.
⚖️ Verdict: 🟢
Bullish. The powerful volume-driven rebound and subsequent guidance raise are strong positive signals that the business has regained its footing after a challenging first half. While the negative price/mix is a point to monitor, it appears to be a manageable issue concentrated in specific areas. The core narrative is one of strengthening brand health and successful execution, which outweighs the persistent drag from the vitamin business.
Key Themes
High-Growth Brands Continue to Dominate
The company's 'Power Brands' remain the primary growth engine. THERABREATH consumption grew 17% in a declining mouthwash category, solidifying its #2 market share position at 21.8%. HERO outpaced a flat acne category with 5.2% consumption growth, maintaining its #1 brand status. Management consistently highlights the low household penetration of these brands (THERABREATH at 11% vs. 65% category; HERO at 9% vs. 28% category) as a key indicator of their long-term growth runway.
Negative Price/Mix Weighs on Growth
A key concern contradicting the positive narrative is the negative price/mix trend, which subtracted 0.6% from overall organic growth and a more significant 1.4% from the Consumer Domestic segment. Management attributes this to deliberate price adjustments to improve the value equation for BATISTE, promotional actions to drive velocity in the struggling vitamin business, and consumers shifting to larger value-sized packs. While strong volume growth is currently offsetting this, it indicates limited pricing power in certain categories.
ARM & HAMMER Value Proposition Gains Traction
Amid a mixed consumer environment, the ARM & HAMMER brand is benefiting from a flight to value. For the first time in eight quarters, the value tier of the laundry detergent category showed positive consumption growth. ARM & HAMMER liquid laundry detergent grew consumption by 1.9% in a flat category, reaching a 15% market share. This performance highlights the strength of the company's balanced portfolio, which can capture value-conscious consumers while its premium brands cater to different segments.
Vitamin Business Remains a Significant Drag
The vitamin business continues to significantly underperform, with declines offsetting growth in other parts of the portfolio. Management is undertaking a strategic review with options including streamlining, a joint venture, or divestiture, with a conclusion expected by the end of 2025. This ongoing weakness is a major headwind and a source of management distraction.
Successful Acquisition and Portfolio Management
The company is actively managing its portfolio for growth. The newly acquired TOUCHLAND hand sanitizer brand delivered results that 'exceeded initial expectations' in its first quarter. Simultaneously, the company is on track with its strategic decision to exit the lower-margin FLAWLESS, SPINBRUSH, and WATERPIK showerhead businesses by early 2026, which is expected to improve the company's overall growth and profitability profile.
Reinvesting Strength to Build Momentum
Following the strong Q3 performance, management is increasing its brand investment. Marketing expense as a percentage of sales rose by 50 basis points to 12.8% in the quarter. For the full year, the company now expects marketing spend to exceed 11% of sales, using the current outperformance to fuel brand momentum heading into 2026.
Navigating a Mixed Macro Environment
CEO Rick Dierker described the consumer backdrop as mixed, with stretched household finances and elevated promotional intensity in some categories, but also relatively low unemployment. The company's categories are growing at around 2%, and CHD's ability to grow organic sales at 3.4% demonstrates that its balanced portfolio of value and premium brands is well-positioned to outperform in the current environment.
Other KPIs
Stable. Adjusted Gross Margin expanded 10 basis points YoY, reversing two consecutive quarters of contraction. The improvement was fueled by productivity programs and the benefit of higher-margin acquisitions, which offset inflation and tariff costs. However, guidance implies a contraction of approximately 50 basis points in Q4.
Accelerating. Cash flow was very strong, increasing 19.6% year-over-year. This robust performance led management to increase the full-year outlook for cash from operations from $1.1 billion to approximately $1.2 billion. The strong cash generation enabled $300 million in share repurchases during the quarter, bringing the year-to-date total to $600 million.
Accelerating. The International division was a standout performer, with organic growth accelerating to 7.7%, driven by a healthy combination of volume (+5.9%) and price/mix (+1.8%). Growth was broad-based across numerous markets and led by the global expansion of the HERO, THERABREATH, and BATISTE brands.
Guidance
Accelerating. The raised full-year guidance implies a Q4 Adjusted EPS of approximately $0.83, representing an 8% increase year-over-year. This indicates a significant acceleration in profitability compared to the 2.5% growth reported in Q3.
Decelerating. The Q4 outlook for ~1.5% organic growth represents a marked slowdown from the 3.4% achieved in Q3. Management attributes this to the impact of lapping a prior-year port strike that inflated sales in Q4 2024, as well as the continued negative trends in the vitamin business.
Stable. The full-year outlook was improved from a 60 bps contraction to a 40 bps contraction. However, this implies that Q4 adjusted gross margin is expected to contract by approximately 50 basis points year-over-year, primarily due to inflation and tariff costs.